Niewisch MR, Savage SA (2019) An update on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert Rev Hematol 12:1037–1052

CAS  PubMed  PubMed Central  Google Scholar 

Alter BP, Giri N, Savage SA, Rosenberg PS (2018) Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up. Haematologica 103:30–39

CAS  PubMed  PubMed Central  Google Scholar 

Agarwal S, Savage SA, Stevens KB (2022) Telomere biology disorders diagnosis and management guidelines. Team Telomere. https://teamtelomere.org/diagnosis-management-guidelines/

Ramos H, Aly MM, Balasubramanian SK (2022) Late presentation of dyskeratosis congenita: germline predisposition to adult-onset secondary acute myeloid leukemia. Hematol Rep 14:294–299

PubMed  PubMed Central  Google Scholar 

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:617–629

CAS  PubMed  Google Scholar 

Ferrer A, Mangaonkar AA, Stroik S, Zimmermann MT, Sigafoos AN, Kamath PS et al (2020) Functional validation of TERT and TERC variants of uncertain significance in patients with short telomere syndromes. Blood Cancer J 10:1–5

Google Scholar 

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405–424

PubMed  PubMed Central  Google Scholar 

Zade NH, Khattar E (2023) POT1 mutations cause differential effects on telomere length leading to opposing disease phenotypes. J Cell Physiol 238:1237–1255

CAS  PubMed  Google Scholar 

Takai H, Jenkinson E, Kabir S, Babul-Hirji R, Najm-Tehrani N, Chitayat DA et al (2016) A POT1 mutation implicates defective telomere end fill-in and telomere truncations in Coats plus. Genes Dev 30:812–826

CAS  PubMed  PubMed Central  Google Scholar 

Revy P, Kannengiesser C, Bertuch AA (2023) Genetics of human telomere biology disorders. Nat Rev Genet 24:86–108

CAS  PubMed  Google Scholar 

Schratz KE, Gaysinskaya V, Cosner ZL, DeBoy EA, Xiang Z, Kasch-Semenza L et al (2021) Somatic reversion impacts myelodysplastic syndromes and acute myeloid leukemia evolution in the short telomere disorders. J Clin Invest 131:e147598

CAS  PubMed  PubMed Central  Google Scholar 

Fioredda F, Iacobelli S, Korthof ET, Knol C, van Biezen A, Bresters D et al (2018) Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita. Br J Haematol 183:110–118

CAS  PubMed  Google Scholar 

Geng J, Zhao M, Li Q (2022) Severe immunochemotherapy-induced toxicities in a patient with dyskeratosis congenita and literature review. Hematology 27:1041–1045

PubMed  Google Scholar 

Ma J, Morimoto K, Pulsipher MA, Parekh C (2023) Venetoclax and azacitidine in the treatment of NPM1-mutated donor cell-derived leukemia in a patient with fanconi anemia: case report and literature review. JCO Precis Oncol 7:e2200693

PubMed  PubMed Central  Google Scholar 

Place AE (2025) A phase I study of venetoclax in combination with cytotoxic chemotherapy, including calaspargase pegol, for children, adolescents and young adults with high-risk hematologic malignancies. clinicaltrials.gov. https://clinicaltrials.gov/study/NCT05292664. Accessed 2 Feb 2025